The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy.

PLoS One

Viral Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.

Published: May 2012

Background: Filoviruses, including Ebola virus, are unusual in being filamentous animal viruses. Structural data on the arrangement, stoichiometry and organisation of the component molecules of filoviruses has until now been lacking, partially due to the need to work under level 4 biological containment. The present study provides unique insights into the structure of this deadly pathogen.

Methodology And Principal Findings: We have investigated the structure of Ebola virus using a combination of cryo-electron microscopy, cryo-electron tomography, sub-tomogram averaging, and single particle image processing. Here we report the three-dimensional structure and architecture of Ebola virus and establish that multiple copies of the RNA genome can be packaged to produce polyploid virus particles, through an extreme degree of length polymorphism. We show that the helical Ebola virus inner nucleocapsid containing RNA and nucleoprotein is stabilized by an outer layer of VP24-VP35 bridges. Elucidation of the structure of the membrane-associated glycoprotein in its native state indicates that the putative receptor-binding site is occluded within the molecule, while a major neutralizing epitope is exposed on its surface proximal to the viral envelope. The matrix protein VP40 forms a regular lattice within the envelope, although its contacts with the nucleocapsid are irregular.

Conclusions: The results of this study demonstrate a modular organization in Ebola virus that accommodates a well-ordered, symmetrical nucleocapsid within a flexible, tubular membrane envelope.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256159PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0029608PLOS

Publication Analysis

Top Keywords

ebola virus
24
virus
7
ebola
5
organisation ebola
4
virus reveals
4
reveals capacity
4
capacity extensive
4
extensive modular
4
modular polyploidy
4
polyploidy background
4

Similar Publications

New reverse sum Revan indices for physicochemical and pharmacokinetic properties of anti-filovirus drugs.

Front Chem

December 2024

Department of Mathematics, School of Advanced Sciences, Vellore Institute of Technology, Chennai, Tamil Nadu, India.

Ebola and Marburg viruses, biosafety level 4 pathogens, cause severe hemorrhaging and organ failure with high mortality. Although some FDA-approved vaccines or therapeutics like Ervebo for Zaire Ebola virus exist, still there is a lack of effective therapeutics that cover all filoviruses, including both Ebola and Marburg viruses. Therefore, some anti-filovirus drugs such as Pinocembrin, Favipiravir, Remdesivir and others are used to manage infections.

View Article and Find Full Text PDF

Nucleocapsid assembly drives Ebola viral factory maturation and dispersion.

Cell

December 2024

Schaller Research Groups, Department of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany; BioQuant, Heidelberg University, Heidelberg, Germany. Electronic address:

Article Synopsis
  • Viral factories (VFs) are membrane-less organelles where negative-sense RNA viruses, like Ebola, replicate and encapsidate their genomes.
  • Using advanced imaging techniques, researchers observed how viral nucleocapsids (NCs) change from loose formations to compact structures during the infection process.
  • The study found that as VFs mature, they become less spherical and more integrated with cellular components, which likely aids in the transportation of NCs for virus budding.
View Article and Find Full Text PDF

Ebola virus (EBOV) causes severe human disease. During late infection, EBOV virions are on the skin's surface; however, the permissive skin cell types and the route of virus translocation to the epidermal surface are unknown. We describe a human skin explant model and demonstrate that EBOV infection of human skin via basal media increases in a time-dependent and dose-dependent manner.

View Article and Find Full Text PDF

Clinical advancements in mRNA vaccines against viral infections.

Clin Immunol

December 2024

Department of Microbiology, Gachon University College of Medicine, Incheon, Republic of Korea; Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea; Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Republic of Korea; Korea mRNA Vaccine Initiative, Gachon University, Seongnam, Republic of Korea. Electronic address:

Over the last decade, mRNA vaccines development has shown significant advancement, particularly during the COVID-19 pandemic. This comprehensive review examines the efficacy of pivotal vaccines against emerging COVID-19 variants and strategies for enhancing vaccine effectiveness. It also explores the versatility of mRNA technology in addressing other infectious diseases such as influenza, respiratory syncytial virus, HIV, cytomegalovirus, Ebola, Zika, Rabies, and Nipah viruses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!